PAHC - Phibro Animal Health Corporation
NASDAQ
->
Healthcare
->
Drug Manufacturers—Specialty & Generic
Teaneck,
United States
Type: Equity
PAHC price evolution
PAHC
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $70.61 | $50.23 | $32.97 | |
| Short term investments | $44 | $48.52 | $59.52 | |
| Net receivables | $160.78 | $169.45 | $161.09 | $150.63 |
| Inventory | $272.56 | $265.91 | $282.29 | $286.68 |
| Total current assets | $570.77 | $601 | $597.18 | $586.59 |
| Long term investments | ||||
| Property, plant & equipment | $243.87 | $240.9 | $202.06 | $200.84 |
| Goodwill & intangible assets | $99.59 | $102.88 | $105.64 | |
| Total noncurrent assets | $381.19 | $381.86 | $386.12 | |
| Total investments | $44 | $48.52 | $59.52 | |
| Total assets | $966.29 | $982.18 | $979.03 | $972.71 |
| Current liabilities | ||||
| Accounts payable | $86.53 | $85.57 | $82.61 | $86.41 |
| Deferred revenue | ||||
| Short long term debt | $29.8 | $29.81 | $26.05 | |
| Total current liabilities | $176.89 | $204.15 | $189.07 | $187.74 |
| Long term debt | $466.67 | $458.29 | $456.01 | $448.85 |
| Total noncurrent liabilities | $521.39 | $519.87 | $514.17 | |
| Total debt | $488.08 | $485.82 | $474.9 | |
| Total liabilities | $707.76 | $725.54 | $708.94 | $701.9 |
| Shareholders' equity | ||||
| Retained earnings | $246 | $243.89 | $248 | $244.45 |
| Other shareholder equity | -$123.94 | -$123.53 | -$114 | -$109.61 |
| Total shareholder equity | $256.64 | $270.09 | $270.8 | |
| (in millions $) | 30 Jul 2024 | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $70.61 | $41.28 | $74.25 | $50.21 |
| Short term investments | $44 | $40 | $17 | $43 |
| Net receivables | $169.45 | $163.48 | $166.54 | $146.85 |
| Inventory | $265.91 | $277.57 | $259.16 | $216.31 |
| Total current assets | $601 | $585.72 | $566.23 | $498.91 |
| Long term investments | ||||
| Property, plant & equipment | $240.9 | $195.57 | $165.49 | $154.71 |
| Goodwill & intangible assets | $99.59 | $108.26 | $117.09 | $114.96 |
| Total noncurrent assets | $381.19 | $385.67 | $365.47 | $342.42 |
| Total investments | $44 | $40 | $17 | $43 |
| Total assets | $982.18 | $971.4 | $931.7 | $841.33 |
| Current liabilities | ||||
| Accounts payable | $85.57 | $73.85 | $95.6 | $68.36 |
| Deferred revenue | ||||
| Short long term debt | $29.8 | $22.3 | $15 | $9.38 |
| Total current liabilities | $204.15 | $176 | $190.83 | $164.12 |
| Long term debt | $458.29 | $452.54 | $417.93 | $382.71 |
| Total noncurrent liabilities | $521.39 | $512.89 | $478.43 | $438.68 |
| Total debt | $488.08 | $474.84 | $432.93 | $392.08 |
| Total liabilities | $725.54 | $688.89 | $669.26 | $602.8 |
| Shareholders' equity | ||||
| Retained earnings | $243.89 | $260.91 | $247.75 | $218.01 |
| Other shareholder equity | -$123.53 | -$114.21 | -$121.11 | -$115.29 |
| Total shareholder equity | $256.64 | $282.51 | $262.44 | $238.53 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $273.16 | $263.22 | $249.94 | |
| Cost of revenue | $186.01 | $183.62 | $171.33 | |
| Gross Profit | $87.15 | $79.6 | $78.62 | |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | $68.73 | $59.68 | $62.91 | |
| Total operating expenses | $68.73 | $59.68 | $62.91 | |
| Operating income | $18.42 | $19.92 | $15.7 | |
| Income from continuing operations | ||||
| EBIT | $11.15 | $17.5 | $8.22 | |
| Income tax expense | $5.66 | $4.52 | $2.29 | |
| Interest expense | $4.74 | $4.58 | $4.66 | |
| Net income | ||||
| Net income | $0.75 | $8.4 | $1.27 | |
| Income (for common shares) | $0.75 | $8.4 | $1.27 | |
| (in millions $) | 31 Dec 2024 | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1017.68 | $977.89 | $942.26 | $833.35 |
| Cost of revenue | $704.59 | $679.65 | $656.86 | $561.97 |
| Gross Profit | $313.09 | $298.24 | $285.4 | $271.38 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | $259.78 | $226.39 | $206.41 | $196.51 |
| Total operating expenses | $259.78 | $226.39 | $206.41 | $196.51 |
| Operating income | $53.31 | $71.85 | $78.99 | $74.87 |
| Income from continuing operations | ||||
| EBIT | $29.45 | $69.39 | $84.2 | $79.35 |
| Income tax expense | $8.5 | $21.46 | $23.15 | $12.08 |
| Interest expense | $18.54 | $15.32 | $11.88 | $12.88 |
| Net income | ||||
| Net income | $2.42 | $32.61 | $49.17 | $54.38 |
| Income (for common shares) | $2.42 | $32.61 | $49.17 | $54.38 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | $0.75 | $8.4 | $1.27 | |
| Operating activities | ||||
| Depreciation | $9.2 | $9.2 | $8.91 | |
| Business acquisitions & disposals | $0.04 | -$3.33 | ||
| Stock-based compensation | $0.18 | $0.14 | $0.08 | |
| Total cash flows from operations | $28.43 | $11.41 | $31.56 | |
| Investing activities | ||||
| Capital expenditures | -$13.07 | -$9.73 | -$10.96 | |
| Investments | $4.52 | $11 | -$11.52 | |
| Total cash flows from investing | -$2.93 | -$9.11 | $1.13 | -$24.86 |
| Financing activities | ||||
| Dividends paid | -$4.86 | -$4.86 | -$4.86 | -$4.86 |
| Sale and purchase of stock | ||||
| Net borrowings | $6.65 | $9.71 | -$9.84 | |
| Total cash flows from financing | -$29.2 | $1.79 | $4.85 | -$14.71 |
| Effect of exchange rate | $0.73 | -$0.72 | -$0.14 | -$2.17 |
| Change in cash and equivalents | -$18.78 | $20.39 | $17.25 | -$10.18 |
| (in millions $) | 31 Dec 2024 | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Net income | $2.42 | $32.61 | $49.17 | $54.38 |
| Operating activities | ||||
| Depreciation | $36.18 | $34.01 | $32.7 | $31.89 |
| Business acquisitions & disposals | -$3.28 | -$13.51 | ||
| Stock-based compensation | $0.47 | $1.13 | ||
| Total cash flows from operations | $87.59 | $13.31 | $31.65 | $48.31 |
| Investing activities | ||||
| Capital expenditures | -$41.24 | -$51.79 | -$37.04 | -$29.32 |
| Investments | -$4 | -$23 | $27.35 | $12 |
| Total cash flows from investing | -$48.19 | -$74.02 | -$22.58 | -$18.58 |
| Financing activities | ||||
| Dividends paid | -$19.44 | -$19.44 | -$19.44 | -$19.43 |
| Sale and purchase of stock | ||||
| Net borrowings | $12.67 | $46.43 | $40.63 | $2.44 |
| Total cash flows from financing | -$6.77 | $26.99 | $16.34 | -$17 |
| Effect of exchange rate | -$3.3 | $0.75 | -$1.37 | $1.14 |
| Change in cash and equivalents | $29.33 | -$32.97 | $24.04 | $13.87 |
News
Fundamentals
| Market cap | $962.37M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 40.50M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 2.83 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 3.23 |
| Quick ratio | 1.69 |